Application of composition in functional dyspepsia

Abstract

The invention provides application of a composition in functional dyspepsia, and belongs to the technical field of traditional Chinese medicines. The composition comprises rhizoma coptidis, cortex magnoliae officinalis, radix aucklandiae and rhizoma zingiberis. The composition specifically comprises the following components in parts by weight: 30-60 parts of coptis chinensis extract, 30-60 parts of mangnolia officinalis extract, 5-20 parts of costus oil and 5-20 parts of dried ginger oil. The four components in the composition have a synergistic effect on regulation of gastrointestinal hormone secretion, and can effectively regulate the problems of insufficient secretion of motilin and gastrin and excessive secretion of somatostatin caused by atropine, so that the gastrointestinal motility is improved, and dyspepsia is relieved.

Description

Technical Field

[0001] The present invention belongs to the technical field of traditional Chinese medicines, and relates to the application of a composition in functional dyspepsia, and specifically relates to the application of a composition in the preparation of a medicine for preventing and / or treating functional dyspepsia. Background Art

[0002] Digestive hormones, also known as gastrointestinal hormones, refer to a series of polypeptide hormones produced by secretory cells on the gastrointestinal mucosa. Gastrointestinal hormones can regulate gastrointestinal motility, secretion of digestive juices, and assist in physiological phenomena such as renewal and nourishment of the gastrointestinal mucosa. Among them, motilin, gastrin and somatostatin are three important gastrointestinal hormones. Motilin (MTL) can promote and affect gastrointestinal motility by stimulating phase III of interdigestive myoelectric activity, thereby affecting the gastrointestinal tract's transport of water and electrolytes. Gastrin (GAS) has the function of stimulating gastric mucosal cell proliferation and promoting gastric antrum and intestinal motility. Somatostatin (SS), a gastrointestinal hormone naturally produced in the human body, can reduce blood flow to internal organs, and has the function of inhibiting the secretion of gastric acid and pepsin and inhibiting the release of gastrin.

[0003] Chinese invention patent CN116077609A provides a Huanghou antidiarrhea quick-release drop pill including active ingredients and excipients, wherein the active ingredients include: coptis extract, magnolia bark extract, costus root oil, and dried ginger oil, and the excipients include: adsorbent, filler, disintegrant and binder. The preparation method is as follows: 1) mix the magnolia bark extract with costus root oil and dried ginger oil, add adsorbent, and prepare microencapsulated oil; 2) add the coptis extract to the microencapsulated oil obtained in step (1), mix, add adsorbent, and prepare a solid; 3) mix the solid obtained in step (2) with filler and disintegrant, add binder, and prepare a soft material; 4) prepare micropills from the soft material obtained in step (3); 5) dry the micropills obtained in step (4), sieve, and obtain. The technology discloses the use of the Huanghou antidiarrhea composition in the preparation of drugs for treating inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS).

[0004] Chinese invention patent CN114191534A provides an application of a composition in the preparation of a drug for treating diabetic gastroparesis. The composition comprises: coptis root, magnolia bark, costusroot, and dried ginger. The composition can be prepared into Huanghou antidiarrhea pills for application.

[0005] However, the prior art does not provide the use of the composition (Coptis chinensis, Magnolia officinalis, Aucklandia lappa and Dry Ginger) in treating functional dyspepsia, especially functional dyspepsia due to disordered gastrointestinal hormone secretion. Summary of the invention

[0006] In view of this, in view of the problem that the prior art does not provide a composition (Coptis chinensis, Magnolia officinalis, Costusroot and Dry Ginger) for use in a drug for treating functional dyspepsia, the object of the present invention is to provide a composition for use in functional dyspepsia.

[0007] To achieve the above-mentioned purpose of the invention, on the one hand, the present invention provides a composition for use in preparing a drug for preventing and / or treating functional dyspepsia, wherein the composition comprises coptis root, magnolia bark, costusroot and dried ginger.

[0008] Preferably, in the composition, the coptis root is coptis root extract, the magnolia bark is magnolia bark extract, the costus root is costus root oil, and the dried ginger is dried ginger oil.

[0009] More preferably, the composition comprises, by weight: 30-60 parts of Coptidis rhizome extract, 30-60 parts of Magnolia officinalis extract, 5-20 parts of costusroot oil and 5-20 parts of dried ginger oil.

[0010] More preferably, the composition comprises, by weight: 36 parts of Coptidis rhizome extract, 36 parts of Magnolia officinalis extract, 9 parts of costusroot oil and 12 parts of dried ginger oil.

[0011] Preferably, the functional dyspepsia includes functional dyspepsia caused by disordered gastrointestinal hormone secretion.

[0012] More preferably, the gastrointestinal hormone secretion disorder is at least one of gastrin below normal, motilin below normal, and somatostatin above normal.

[0013] The “normal value” refers to the numerical range of each index (including serum gastrin, serum motilin and serum somatostatin) of the subject in a healthy state. The “lower than normal value” of an index refers to the lower than the lowest value of the index numerical range of the subject in a healthy state. The “higher than normal value” of an index refers to the higher than the highest value of the index numerical range of the subject in a healthy state.

[0014] More preferably, the gastrointestinal hormone secretion disorder includes gastrointestinal hormone secretion disorder induced by chemicals.

[0015] Still more preferably, the chemical is atropine.

[0016] Preferably, the treatment of functional dyspepsia includes improving the decreased gastric emptying rate caused by gastrointestinal hormone secretion disorder.

[0017] Preferably, the treatment of functional dyspepsia includes improving the decreased intestinal propulsion rate caused by gastrointestinal hormone secretion disorder.

[0018] Preferably, the composition is Huanghou Antidiarrhea Drop Pills.

[0019] Compared with the prior art, the present invention has the following beneficial effects:

[0020] The present invention provides the use of a composition with coptis root, magnolia bark, costus root and dried ginger as effective ingredients in a drug for preventing and / or treating functional dyspepsia, in particular, in the preparation of a drug for treating insufficient secretion of gastrointestinal hormones. Magnolia bark is the main ingredient, which exerts the effects of aromatic bitter purgation, promoting qi and eliminating accumulation, and drying dampness and removing fullness; coptis root is the minister, which is very bitter and cold, bitter in taste and dry in nature, clearing away heat and dampness, purging fire and detoxifying; dried ginger is the minister, which is hot and dry in nature, warming the middle and dispersing cold, and invigorating spleen yang; costus root is the adjuvant, which is pungent and dispersing, bitter and descending, warming and unblocking, and has aromatic gas, which can rise and fall. Animal experiments show that the compatibility of the four traditional Chinese medicine ingredients within a certain proportion range can play a synergistic role, effectively improving the phenomenon of the disordered secretion of three gastrointestinal hormones, gastrin, motilin and somatostatin, caused by atropine, and thus improving the functional dyspepsia of the test animals. DETAILED DESCRIPTION

[0021] The following non-limiting examples can enable those skilled in the art to more fully understand the present invention, but do not limit the present invention in any way. The following content is merely an exemplary description of the scope of the present invention, and those skilled in the art can make various changes and modifications to the present invention based on the disclosed content, which should also fall within the scope of the present invention.

[0022] The present invention is further described below by way of specific examples. The various chemical reagents used in the examples of the present invention are obtained through conventional commercial channels unless otherwise specified. Unless otherwise specified, the contents described below are all weight contents. Unless otherwise specified, it is understood that the process is carried out at room temperature.

[0023] In the following examples, the sources of raw materials are shown in Table 1.

[0024] Table 1

[0025]

[0026] Example 1

[0027] 36 parts of Coptis chinensis extract, 36 parts of Magnolia officinalis extract, 9 parts of costusroot oil, and 12 parts of dried ginger oil.

[0028] Example 2

[0029] 30 parts of Coptis chinensis extract, 60 parts of Magnolia officinalis extract, 5 parts of costusroot oil, and 20 parts of dried ginger oil.

[0030] Example 3

[0031] 60 parts of Coptis chinensis extract, 30 parts of Magnolia officinalis extract, 20 parts of costusroot oil, and 5 parts of dried ginger oil.

[0032] Comparative Example 1

[0033] 25 parts of Coptis chinensis extract, 65 parts of Magnolia officinalis extract, 2 parts of costus root oil, 23 parts of dried ginger oil.

[0034] Control Group 2

[0035] 65 parts of Coptis chinensis extract, 25 parts of Magnolia officinalis extract, 23 parts of costus root oil, 2 parts of dried ginger oil.

[0036] Control Group 3

[0037] 36 parts of Coptis chinensis extract, 12 parts of dried ginger oil.

[0038] Control Group 4

[0039] 36 parts of Coptis chinensis extract, 9 parts of costus root oil.

[0040] Control Group 5

[0041] 9 parts of costus root oil, 12 parts of dried ginger oil.

[0042] Control Group 6

[0043] 36 parts of Coptis chinensis extract, 36 parts of Magnolia officinalis extract.

[0044] Effect Evaluation

[0045] 1. Test Method

[0046] 1.1 Experimental Animals

[0047] Male Balb / c mice (Animal License No.: SCXK(E)2022 - 0012; Certificate No.: No.42010200009984), 9 - week - old, weighing 20 - 25 g. After 1 - week of adaptive feeding, their weights were measured, and mice with weights of 22 ± 2 g were selected for the experiment.

[0048] 1.2 Grouping and Treatment

[0049] The qualified mice were randomly grouped, with 12 mice in each group.

[0050] Blank Group: 12 mice; gavaged with sodium chloride injection (normal saline) for 7 days;

[0051] Model Group: 12 mice; gavaged with sodium chloride injection (normal saline) for 7 days, and then modeled by intraperitoneal injection of atropine sulfate at 1.5 mg / kg after 7 days;

[0052] Mosapride Group (calculated as mosapride citrate at 4 mg / kg / day): 12 mice; gavaged with mosapride citrate for 7 days, and then modeled by intraperitoneal injection of atropine sulfate at 1.5 mg / kg after 7 days;

[0053] The dosages of the Chinese medicinal ingredients / Chinese medicinal composition ingredients involved in the following groups are all based on the weight of the Chinese medicinal ingredients / compositions corresponding to each group, and the unit is mg / kg mouse body weight / day, abbreviated as mg / kg / day.

[0054] The medium dose group in Example 1: 12 mice; the medium dose (9 mg / kg / day) of the composition provided in Example 1 was gavaged for 7 days, and 1.5 mg / kg of atropine sulfate was injected intraperitoneally after 7 days to establish the model; the preparation method of the composition for gavage is as follows: 36 parts of Coptis chinensis extract, 36 parts of Magnolia officinalis extract, 9 parts of costus root oil, 12 parts of dried ginger oil and an appropriate amount of sodium chloride injection (normal saline) were mixed, vortexed to mix well, and prepared into a suspension with a concentration of 1.8 mg / mL, and diluted with warm normal saline (35-38°C) to a concentration of 0.9 mg / mL, and used immediately after preparation.

[0055] Example 1 High-dose group: 12 mice; the high-dose composition provided in the example (18 mg / kg / day) was gavaged for 7 days, and 1.5 mg / kg of atropine sulfate was injected intraperitoneally after 7 days to establish the model; the preparation method of the composition for gavage is as follows: 36 parts of Coptis chinensis extract, 36 parts of Magnolia officinalis extract, 9 parts of costus root oil, 12 parts of dried ginger oil are mixed with an appropriate amount of sodium chloride injection (normal saline), vortexed to mix thoroughly, and prepared into a suspension with a concentration of 1.8 mg / mL, which is prepared and used immediately.

[0056] Example 2 Group (18 mg / kg / day): 12 mice; gavage for 7 days, and intraperitoneal injection of 1.5 mg / kg atropine sulfate to establish the model after 7 days; the preparation method of the composition for gavage is as follows: 30 parts of Coptis chinensis extract, 60 parts of Magnolia officinalis extract, 5 parts of costusroot oil, 20 parts of dried ginger oil are mixed with an appropriate amount of sodium chloride injection (normal saline), vortexed to mix well, and prepared into a suspension with a concentration of 1.8 mg / mL, which is prepared and used immediately.

[0057] Example 3 Group (18 mg / kg / day): 12 mice; gavage for 7 days, and intraperitoneal injection of 1.5 mg / kg atropine sulfate to establish the model after 7 days; the preparation method of the composition for gavage is as follows: 60 parts of Coptis chinensis extract, 30 parts of Magnolia officinalis extract, 20 parts of costusroot oil, 5 parts of dried ginger oil are mixed with an appropriate amount of sodium chloride injection (normal saline), vortexed to mix well, and prepared into a suspension with a concentration of 1.8 mg / mL, which is used immediately after preparation.

[0058] Comparative Example 1 (18 mg / kg / day): 12 mice; gavage for 7 days, and intraperitoneal injection of 1.5 mg / kg of atropine sulfate to establish the model after 7 days; the preparation method of the composition for gavage is as follows: 25 parts of Coptis chinensis extract, 65 parts of Magnolia officinalis extract, 2 parts of costus root oil, 23 parts of dried ginger oil are mixed with an appropriate amount of sodium chloride injection (normal saline), vortexed to mix well, and prepared into a suspension with a concentration of 1.8 mg / mL, which is prepared and used immediately.

[0059] Comparative Example 2 (18 mg / kg / day): 12 mice; gavage for 7 days, and intraperitoneal injection of 1.5 mg / kg of atropine sulfate to establish the model after 7 days; the preparation method of the composition for gavage is as follows: 65 parts of Coptis chinensis extract, 25 parts of Magnolia officinalis extract, 23 parts of costus root oil, 2 parts of dried ginger oil are mixed with an appropriate amount of sodium chloride injection (normal saline), vortexed to mix well, and prepared into a suspension with a concentration of 1.8 mg / mL, which is prepared and used immediately.

[0060] Comparative Example 3 (Coptis rhizome and dried ginger drug pair) (9.29 mg / kg / day): 12 mice; gavage for 7 days, and intraperitoneal injection of 1.5 mg / kg of atropine sulfate to establish the model after 7 days; the preparation method of the composition for gavage is as follows: 36 parts of Coptis rhizome extract, 12 parts of dried ginger oil and an appropriate amount of sodium chloride injection (normal saline) are mixed, vortexed to mix thoroughly, and prepared into a suspension with a concentration of 0.93 mg / mL, which is prepared and used immediately.

[0061] Comparative Example 4 (Rhizoma Coptidis and Aucklandiae drug pair) (8.71 mg / kg / day): 12 mice; gavage for 7 days, and intraperitoneal injection of 1.5 mg / kg of atropine sulfate to establish a model after 7 days; the preparation method of the composition for gavage is as follows: 36 parts of Rhizoma Coptidis extract, 9 parts of Aucklandiae oil and an appropriate amount of sodium chloride injection (normal saline) are mixed, vortexed to mix thoroughly, and prepared into a suspension with a concentration of 0.87 mg / mL, which is prepared and used immediately.

[0062] Comparative Example 5 (costus root and dried ginger drug pair) (4.06 mg / kg / day): 12 mice; gavage for 7 days, and intraperitoneal injection of 1.5 mg / kg of atropine sulfate to establish the model after 7 days; the preparation method of the composition for gavage is as follows: 9 parts of costus root oil and 12 parts of dried ginger oil are mixed with an appropriate amount of sodium chloride injection (normal saline), vortexed to mix thoroughly, and prepared into a suspension with a concentration of 0.41 mg / mL, which is prepared and used immediately.

[0063] Comparative Example 6 (Coptis rhizoma and Magnolia officinalis drug pair) (13.94 mg / kg / day): 12 mice; gavage for 7 days, and intraperitoneal injection of 1.5 mg / kg of atropine sulfate to establish the model after 7 days; the preparation method of the composition for gavage is as follows: 36 parts of Coptis rhizoma extract and 36 parts of Magnolia officinalis extract are mixed with an appropriate amount of sodium chloride injection (normal saline), vortexed to mix thoroughly, and prepared into a suspension with a concentration of 1.39 mg / mL, which is prepared and used immediately.

[0064] Rhizoma Coptidis group (6.97 mg / kg / day): 12 mice; the Rhizoma Coptidis extract suspension was gavaged for 7 days, and 1.5 mg / kg atropine sulfate was injected intraperitoneally 7 days later to establish the model; the Rhizoma Coptidis extract suspension was prepared as follows: 36 portions of Rhizoma Coptidis extract were prepared into a suspension with a concentration of 0.70 mg / mL, which was prepared and used immediately.

[0065] Dry ginger group (2.32 mg / kg / day): 12 rats; dry ginger oil suspension was gavaged for 7 days, and 1.5 mg / kg atropine sulfate was injected intraperitoneally 7 days later to establish the model; the preparation method of dry ginger oil suspension was as follows: 12 portions of dry ginger oil were taken and prepared into a suspension with a concentration of 0.23 mg / mL, which was prepared and used immediately.

[0066] Costus root group (1.74 mg / kg / day): 12 mice; costus root oil suspension was gavaged for 7 days, and 1.5 mg / kg atropine sulfate was injected intraperitoneally 7 days later to establish the model; the costus root oil suspension was prepared as follows: 9 parts of costus root oil were taken and prepared into a suspension with a concentration of 0.17 mg / mL, which was prepared and used immediately.

[0067] Magnolia bark group (6.97 mg / kg / day): 12 mice; Magnolia bark homemade pills were gavaged for 7 days, and 1.5 mg / kg atropine sulfate was injected intraperitoneally after 7 days to establish the model; the preparation method of Magnolia bark extract suspension is as follows: 36 portions of Magnolia bark extract were prepared into a suspension with a concentration of 0.70 mg / mL, which was prepared and used immediately.

[0068] 1.3 Test process

[0069] The gavage treatment was carried out according to the gavage method in "1.2, Grouping Treatment". The mice were fasted but not watered for 12 hours before the experiment on the 8th day. When modeling, the blank group was intraperitoneally injected with 0.2 mL of normal saline, and the other groups were intraperitoneally injected with 0.2 mL of atropine sulfate 1.5 mg / kg for modeling. After 20 minutes, all mice were gavaged with 0.4 mL of the prepared dextran blue (BD) 2000 solution (20 mg / mL). 20 minutes after gavage with dextran blue 2000, blood was collected from the fundus venous plexus of the mice, and the blood samples were stored at 4°C. The mice were killed by cervical dislocation and the gastric emptying rate and intestinal propulsion rate were tested.

[0070] 1.4. Serological index testing.

[0071] The concentrations of motilin (MTL), gastrin (GAS) and somatostatin (SS) in the collected blood samples were detected using ELISA detection kits.

[0072] 1.5. Gastric emptying rate detection.

[0073] After killing the animal, open the abdomen quickly to take out the whole stomach, dissolve its contents in 4mL ultrapure water, centrifuge at 3500r / min for 15min, take the supernatant and measure the absorbance value at a wavelength of 620nm with a spectrophotometer. Take another test tube with 0.4mL of the same concentration (BD) 2000 solution, centrifuge under the same conditions, take the supernatant and measure the absorbance value, and use it as the standard tube. According to the formula

[0074] Gastric emptying rate = (1-absorbance of residual pigment in stomach ÷ absorbance of pigment in standard tube) × 100%

[0075] To calculate the gastric pigment emptying rate.

[0076] 1.6. Intestinal propulsion rate detection.

[0077] After killing the animal, quickly take the whole intestine from the pyloric sphincter to the end of the intestine, place it on a glass plate moistened with physiological saline, gently peel it off, and flatten it without any traction. Quickly measure the distance from the pyloric sphincter of the mouse to the front end of the pigment push and the distance from the pyloric sphincter to the end of the intestine, according to the formula:

[0078] Intestinal advancement distance (cm) ÷ total intestinal length (cm) × 100%

[0079] to calculate the intestinal propulsion rate.

[0080] 1.7 Statistical analysis

[0081] All experimental results were presented as mean ± standard deviation. The experimental data were analyzed using Graph-pad Prism8.0 software, and the statistical differences between each group and the control group were compared using one-way analysis of variance (ANOVA) and Dunnett's t test.

[0082] 2. Test results.

[0083] 2.1. Effects of different compositions on serum gastrointestinal hormone concentrations in mice.

[0084] The effects of administration on serum gastrointestinal hormones in each group of mice are shown in Table 2 (“-” indicates no intragastric administration).

[0085] Table 2

[0086]

[0087] Among them, ** indicates significant difference compared with the blank group and P < 0.01; ## It means that there is a significant difference compared with the model group and P < 0.01. # Indicates significant difference compared with the model group and P < 0.05; && This indicates that there is a significant difference compared with the high-dose group in Example 1 and P < 0.01. & It indicates that there is a significant difference compared with the high-dose group in Example 1 and P < 0.05; $ Indicates that there is a significant difference compared with the Example 2 group and P < 0.05; p It indicates that there is a significant difference compared with the group 3 of Example 3 and P < 0.05.

[0088] As shown in Table 2, compared with the blank group, the serum SS level of the mice in the model group was significantly increased, and the GAS level and MLT level were significantly decreased. Compared with the model group, the various indicators of serum gastrointestinal hormones of the mice in the mosapride group, the medium dose group, the high dose group of Example 1, the Example 2 group, and the Example 3 group were significantly improved; compared with the high dose group of Example 1, the SS level of the mice in the comparative example 1 group to the comparative example 6 group, the coptis group, the magnolia bark group, the dried ginger group, and the costus root group were significantly increased, and the GAS level and MLT level were significantly decreased (P <

[0089] 0.01~0.05); at the same time, compared with Example 2 and 3, the somatostatin levels of mice in Comparative Example 1 to Comparative Example 6, Coptis chinensis group, Magnolia officinalis group, Dry ginger group and Aucklandia lappa group were also significantly improved, indicating that the four Chinese medicinal ingredients in the composition work synergistically and need to be within a certain range to achieve better improvement effects. It shows that the high dose of Example 1 and the composition described in Example 2 and Example 3 have a good improvement effect on the atropine-induced disorder of gastrointestinal hormone secretion in mice.

[0090] 2.2. Effects of different compositions on gastric emptying and intestinal propulsion function in mice.

[0091] The test results of the effects of administration on gastric emptying and intestinal propulsion function of mice in each group are shown in Table 3 ("-" indicates no intragastric administration).

[0092] Table 3

[0093]

[0094] Among them, ** indicates significant difference compared with the blank group and P < 0.01; ## It means that there is a significant difference compared with the model group and P < 0.01. # Indicates significant difference compared with the model group and P < 0.05; && This indicates that there is a significant difference compared with the high-dose group in Example 1 and P < 0.01. & It indicates that there is a significant difference compared with the high-dose group in Example 1 and P < 0.05; $ Indicates that there is a significant difference compared with the Example 2 group and P < 0.05; p It indicates that there is a significant difference compared with the group 3 of Example 3 and P < 0.05.

[0095] As shown in Table 3, compared with the blank group, the gastric emptying rate and intestinal propulsion rate of the model group mice under the induction of atropine were significantly reduced. Compared with the model group, the gastric emptying rate and intestinal propulsion rate of the mosapride group mice were significantly increased, indicating that atropine induced functional dyspepsia in mice, and mosapride can alleviate this phenomenon. After administration, it can be seen that the gastric emptying rate of the mice in the medium dose, high dose group, embodiment 2 group, and embodiment 3 group of Example 1 is significantly increased, and the intestinal propulsion rate of the mice in the medium dose, high dose group, embodiment 2 group, and embodiment 3 group of Example 1 is significantly increased. Compared with the high dose group of Example 1, the gastric emptying rate and intestinal propulsion rate of the mice in the comparative example 1 group-comparative example 6 group, costus root group, dried ginger group, coptis root group, and magnolia bark group are significantly reduced. At the same time, compared with the examples 2 and 3 groups, the intestinal propulsion rate of the mice in the comparative example 1 group-comparative example 6 group, coptis root group, magnolia bark group, dried ginger group, and costus root group is also significantly reduced, indicating that the various medicinal tastes in the prescription work synergistically and need to be within a certain ratio range to achieve better improvement effects. Therefore, the compositions provided by the high-dose group of Example 1, the group of Example 2 and the group of Example 3 all have good therapeutic effects on atropine-induced functional dyspepsia in mice.

[0096] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.

Claims

1. Use of a composition in the preparation of a medicament for preventing and / or treating functional dyspepsia, characterized in that: The composition includes coptis root, magnolia bark, costusroot and dried ginger.

2. The use according to claim 1, characterized in that: The coptis root is coptis root extract, the magnolia bark is magnolia bark extract, the costus root is costus root oil, and the dried ginger is dried ginger oil.

3. The use according to claim 2, characterized in that: The composition comprises, by weight, 30-60 parts of coptis root extract, 30-60 parts of magnolia bark extract, 5-20 parts of costusroot oil and 5-20 parts of dried ginger oil.

4. The use according to claim 3, characterized in that: The composition comprises, by weight, 36 parts of coptis root extract, 36 parts of magnolia bark extract, 9 parts of costusroot oil and 12 parts of dried ginger oil.

5. The use according to claim 1, characterized in that: The functional dyspepsia includes functional dyspepsia caused by gastrointestinal hormone secretion disorder.

6. The use according to claim 5, characterized in that: The gastrointestinal hormone secretion disorder is at least one of gastrin lower than normal, motilin lower than normal, and somatostatin higher than normal.

7. The use according to claim 5, characterized in that: The gastrointestinal hormone secretion disorder includes the gastrointestinal hormone secretion disorder caused by chemicals.

8. The use according to claim 7, characterized in that: The chemical is atropine.

9. The use according to claim 1, characterized in that: The treatment of functional dyspepsia includes improving the decreased gastric emptying rate caused by gastrointestinal hormone secretion disorder.

10. The use according to claim 1, characterized in that: The treatment of functional dyspepsia includes improving the decreased intestinal propulsion rate caused by gastrointestinal hormone secretion disorder.

11. The use according to claim 1, characterized in that: The composition is Huanghou Antidiarrhea Drop Pills.

Images